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TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous 
mutations in TNFAIP3 cause a haploinsufficiency of A20 (HA20), inadequate inhibition 
of NF-κB pathway, and an early onset autoinflammatory disorder. However, the clinical 
phenotype of patients with HA20 varies greatly and clinical diagnoses prior to establishing 
the genetic cause, included both autoimmune and autoinflammatory conditions. Here, 
we present the first patient with HA20, who was previously diagnosed with AOSD but 
was later found to have a novel heterozygous variant in TNFAIP3 and who was success-
fully treated with anti-IL6 receptor biologic tocilizumab (RoActemra). We discovered a 
novel heterozygous mutation in TNFAIP3 c.1906C>T, not previously found in ExAC data-
base. Further analysis shows that this single-nucleotide variant at the terminal residue 
of TNFAIP3 exon 7 produces an alternatively spliced mRNA resulting in p.His636fsTer1. 
Additional genetic analysis of family members shows that this variant does segregate 
with the inflammatory clinical phenotypes. Subsequent functional test show that NF-κB 
activation, measured as intracellular phosphorylation of p65 in CD14 + monocytes, was 
more enhanced in the patient compared with healthy controls (HC) following stimulation 
with LPS. This was associated with higher production of inflammatory cytokines by 
the patients PBMC in response to LPS and ATP and enhanced activation of NLRP3 
inflammasome complex. Furthermore, increased activation of NLRP3 inflammasome 
was evident systemically, since we detected higher levels of ASC specks in patients’ 
sera compared with HC. Finally, we used population genetics data from GnomAD to 
construct a map of both genetic conservation and most probable disease-causing 
variants in TNFAIP3 which might be found in future cases of HA20.
Keywords: TNFAIP3, A20, AOSD, tocilizumab, autoinflammatory
Abbreviations: ACPA, anti-citrullinated peptide antibodies; ANA, antinuclear antibody; AOSD, adult-onset Still’s disease; BD, 
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IKKγ, inhibitor of nuclear factor kappa B kinase subunit gamma; JIA, juvenile idiopathic arthritis; LOF, loss-of-function; 
MRF, mutation rate residue frequency; NF-κB, nuclear factor kappa B; pLi, probability of loss-of-function intolerance; RA, 
rheumatoid arthritis; RF, rheumatoid factor; RIPK1, receptor-interacting protein kinase 1; SLE, systemic lupus erythematosus.
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1. BACKGROUND
The protein A20, encoded by TNFAIP3, plays a crucial role in the 
negative regulation of inflammation and immunity (1). With its 
deubiquitinase enzyme activity, A20 is a critical inhibitor of pro-
inflammatory signaling pathways, acting on signaling molecules 
including inhibitor of nuclear factor kappa B (NF-κB) kinase 
subunit gamma [IKKγ (NEMO)], TRAF6, and receptor-inter-
acting protein kinase 1 (RIPK1) (2). A20 deubiquitination nega-
tively regulates the NF-κB pathway by hydrolyzing K63-linked 
polyubiquitin chains which would otherwise allow signaling- 
complex formation, while its E3 ligase activity has been shown to 
conjugate substrates including IKKγ with K48-linked ubiquitin 
chains to target them for proteasomal degradation, and therefore 
preventing phosphorylation of IκB and translocation of NF-κB 
(2, 3). A20 haploinsufficiency (HA20) has been recently identified 
as a cause of early-onset autoinflammatory disease (4). The role 
of A20 in ubiquitin-dependent disease and otulipenia in NF-κB-
dependent autoinflammatory disease has been summarized 
recently (5).
The clinical phenotype of patients with HA20 varies greatly. 
The diagnoses in these cases, prior to establishing the genetic 
cause, included both autoimmune and autoinflammatory disor-
ders and ranged from Behçet’s disease (BD), hereditary fever-like 
condition, juvenile idiopathic arthritis (JIA) to systemic lupus 
erythematosus (SLE), and rheumatoid arthritis (RA) (5, 6); 
however, no patients with HA20 have previously been diagnosed 
with adult-onset Stills’ disease (AOSD). Here, we present the first 
patient with HA20, who was previously diagnosed with AOSD 
but later found to have a novel heterozygous variant in TNFAIP3 
and who was successfully treated with anti-IL6 receptor biologic 
tocilizumab (RoActemra).
Gene essentiality is measured by quantifying the rate of loss-
of-function (LoF) variants from population genetics data. The 
probability of loss-of-function intolerance (pLi) score for A20 
is equal to 1, indicating its intolerance to haploinsufficiency (7). 
Considering the heterogeneity of HA20 phenotypes and the diffi-
culties in pre-selecting patients for genetic testing, we are likely to 
find many additional cases of HA20. We used population genetics 
data from GnomAD to construct a map of both genetic conserva-
tion and variant probability. Having a useful guide to predict the 
presentation of these novel variants and allow for pre-emptive 
functional investigations, should aid the diagnosis of such cases 
in the future.
2. CASE PRESENTATION
A 32-year-old female patient initially presented at the age of 
16 with high fever and severe abdominal pain associated with 
anorexia, but not diarrhea and vomiting. Over the period of 
the next 4  years, she had multiple hospital admission with 
similar presentation, which was always accompanied with raised 
C-reactive protein (CRP). On few occasions her urine dipstick 
showed traces of protein, and consequently she was treated for 
presumed urinary sepsis. However, multiple blood and urinary 
cultures were negative, other investigations including abdominal 
ultrasound showed no obvious intraabdominal pathology, and the 
diagnosis remained inconclusive. At the age of 21, she developed 
sudden onset polyarthritis, fever, and wide spread erythematous 
skin rash. The routine investigations at the time showed highly 
elevated acute phase response with CRP > 200 mg/L and hyper-
ferritinemia. Additional investigations including antinuclear 
antibody (ANA), rheumatoid factor (RF), and anti-citrullinated 
peptide antibodies (ACPA) were all negative. Diagnosis of AOSD 
was at that point established, based on the typical clinical features 
associated with hyperferritinemia and exclusion other autoim-
mune rheumatological diagnoses. Her condition improved fol-
lowing initial treatment with oral corticosteroids (prednisolone 
40 mg daily), but she remained dependant on prednisolone for the 
disease control despite attempts to introduce disease-modifying 
antirheumatic drugs (DMARDs) such as hydroxychloroquine, 
azathioprine, and methotrexate, which were all largely ineffective. 
Over the next several years, she continued to suffer from inflam-
matory polyarthritis affecting predominantly the large joints (hips 
and knees). Prior to establishing her genetic diagnosis, the patient 
was eventually treated with tocilizumab to which she made an 
excellent response. She discontinued long-term corticosteroid 
treatment and remains well controlled on monotherapy with 
tocilizumab (IV 8 mg/kg monthly) for the last 2 years.
Subsequent enquiries into her family history revealed that 
she has two children, a boy aged 6 and a half and a girl of age 
4 years. Both children had history of unexplained inflammatory 
symptoms. The girl was symptomatic from the age of 8 months, 
at which point she begun having recurrent episodes of feeling 
generally unwell, with malaise and high fever up to 40°C. The fre-
quency of these episodes varied between 2 and 4 weeks, and each 
episode was relatively short-lived, lasting anywhere between 2 and 
3 days. On few occasions, the episodes of fever were associated 
with erythematous macular rash and mouth ulcers. Subsequently, 
she also developed episodic abdominal pain as well as difficulty 
walking due to the pain in her knees. All these symptoms would 
disappear when the fevers resolved and she would fully recover 
in between these episodes. Since commencing regular colchicine, 
she has not had any further inflammatory episodes or symptoms. 
Her brother was well until age 5 when, like his sister he started 
with monthly episodes of high fever lasting between several hours 
to several days. On few occasions, these episodes were associated 
with vomiting, mouth ulcers, and interestingly, salmon-pink skin 
rash. He was also commenced on colchicine, which in his case has 
not been as effective, and he is currently awaiting therapeutic trial 
of tocilizumab. Finally, the father of the index case also appears to 
have relevant clinical history. He was diagnosed with early onset 
RA, but the details of symptoms and investigations leading to his 
diagnosis are lacking since he is looked after by another hospital 
and he has minimal contact with his daughter with who he has 
not shared any further details regarding his health.
3. CLINICAL AND LABORATORY 
INVESTIGATIONS
The patient received genetic testing after purifying proband 
genomic DNA from whole blood using QIAamp DNA Blood 
kit (Qiagen). Exome sequencing was performed using Agilent 
FIGURE 1 | An exonic splice variant in TNFAIP3 results in deletion of exon 8 in cDNA and A20 haploinsufficiency. (A) The Sanger sequences of gDNA in family 
members showing disease segregation. (B) cDNA of proband with separated wild-type and splice variant alleles showing deletion of exon 8. (C) Western blot 
analysis of proband and two healthy controls showing HA20. (D) Gene structure of A20 cDNA showing functional domains and the resulting splice variant. Protein 
purified from PBMCs using sodium orthanovanadate, Complete Protease Inhibitor Cocktail and PMSF (Sigma), with RIPA buffer. Western blotting used an antibody 
to A20/TNFAIP3 (D13H3) (N-term) Rabbit mAb 5630S (Cell Signaling Technology). The Novex Mini Gel Tank and blot module, Bolt 4–12% Bis–Tris Plus Gels, and 
PVDF Transfer Membrane (Thermo Fisher Scientific). Imaging used Super Signal West Femto/Pico (Thermo Fisher Scientific).
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SureSelectXT with All Exon v5 capture library and sequenced 
on Illumina HiSeq 3000 for 2 ×  150-bp paired-end sequenc-
ing. A novel heterozygous variant was identified in TNFAIP3; 
ENST00000237289 c.1906C>T (GRCh37 6:138200488 rs2001-
38 929). This variant was not found in ExAC database and has 
allele frequency 2.191e−5 on GnomAD. The proband’s two chil-
dren also showed a similar phenotype and were also investigated 
for autosomal dominant inheritance. Genetic analysis of family 
members found segregation with the inflammatory clinical pheno-
types (Figure 1A). PCR clean-up was performed with ExoSAP-IT 
(Affymetrix). Sanger sequencing using BigDye Terminator Cycle 
Sequencing Kit, version 3.1 (Applied Biosystems) and analysis on 
an ABI 3130XL DNA analyzer (Applied Biosystems).
The single-nucleotide variant (SNV) c.1906C>T was first thou-
ght to cause a missense mutation. However, further analysis shows 
that this SNV occurs as the terminal residue of TNFAIP3 exon 7 
(n.1972 Cgt/Tgt) and produces an alternatively spliced mRNA 
transcript resulting in c.1906 Cat/TAG, p.His636fsTer1. To assess 
mRNA splicing, we used cDNA synthesized from the proband’s 
PBMCs and compared with healthy control (HC). The patient’s 
cDNA produced a mutant allele containing deletion of exon 8 
(Figure  1B). Loss of transcript by nonsense-mediated decay 
resulting in A20 haploinsufficiency was confirmed by Western 
blot (Figure  1C). The gene structure of A20 is illustrated in 
Figure 1D. Gel purification of DNA used PureLink™ Quick Gel 
Extraction Kit (Thermo Fisher Scientific). cDNA was synthesized 
using the GoScript™ Reverse Transcriptase kit (Promega).
Previous studies have shown that patients with HA20 show 
enhanced activation of NF-κB and consequently produce higher 
levels of various pro-inflammatory cytokines. Therefore, we 
studied NF-κB activation using flow cytometry (Phosflow system, 
BD Biosciences) by measuring intracellular phosphorylation of 
p65 in CD14 + monocytes in response to stimulation with LPS. 
Following stimulation, greater percentage of patient monocytes 
became p65 positive compared with monocytes from healthy 
controls. However, this did not reach a statistical significance 
(Figure  2). Similarly, spontaneous phosphorylation of p65 
NF-κB has been recently reported for a patient with TNFAIP3 
deletion (8).
To determine if this tendency toward enhanced NF-κB 
activation was associated with increase in cytokine produc-
tion, the purified PBMC from the patient and HC were treated 
with a combination of LPS and ATP and various cytokines 
were measured by ELISA (Thermo Fisher Scientific, IL-1β 
and IL-18) and by multiplexed particle based flow cytometry 
[Fluorokinemap (R&D Systems) on a Luminex analyzer (Bio-
Plex, Bio-Rad, UK)].
The combination of LPS and ATP was used since we also wanted 
to investigate activation of NACHT, LRR, and PYD domain- 
containing protein 3 (NLRP3) inflammasome complex. The 
NLRP3 inflammasome, which is responsible for processing of pro-
IL-1β and pro-IL-18 into their active components, is known to be 
regulated by A20 (9, 10). Furthermore, in patients with HA20, the 
NLRP3 inflammasome was previously shown to be constitutively 
activated (4).
The production of IL-1β and IL-18 was found to be signifi-
cantly increased in the patient’s PBMC compared with healthy 
controls after stimulation by priming and activation with LPS 
and ATP, respectively (Figures 3A,B). This effect was attenu-
ated if the cells were pre-treated with the NLRP3 inhibitor, 
FIGURE 2 | Increased NF-κB phospho-p65 response in A20 
haploinsufficiency. The difference in percentage change of cells positive for 
CD14 and phospho-p65 from unstimulated to stimulated, for healthy controls 
and A20 proband. Representing three independent experiments. Phosflow 
with PBMCs were stimulated for 15 min at 37°C with 100 ng/mL LPS 
(Invivogen, UK). BD Phosflow Fixing and BD Phosflow Perm Buffer III (BD 
Biosciences) were used in combination with aqua dye Live/Dead Fixable cell 
stain kit (Invitrogen, UK). Antibodies: CD19 BV421 (Cat No. 562440—clone 
HIB19); CD3 FITC (Cat No. 555332—clone UCHT1); CD14 AF700 (Cat No. 
557923—clone M5E2); CD4 APC-Cy7 (Cat No. 341115—clone SK3/Leu3a); 
phosphorylated-p65 PE anti-NF-κB pS529 (Cat No. 558423). The BD LSRII 
4 laser instrument was used and analyzed with FACS Diva (BD Biosciences).
4
Lawless et al. AOSD due to HA20
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1527
MCC950, thus confirming that IL-1β and IL-18 production was 
dependant on NLRP3 inflammasome activation. A significant 
response was also measured in TNFα, and IL-10 but interest-
ingly not in IL-6 (Figures 3C–E). Similarly, the production of 
pro-inflammatory cytokines IL-17α and IL-1α and chemokine 
IL-8 were all increased compared with healthy controls 
(Figures 3F–H).
To determine if enhanced NLRP3 inflammasome activation 
is also evident systemically, we investigated the patient’s serum 
and found increased release of apoptosis associated speck-like 
protein containing a CARD (ASC) specks, which are typically 
released by cells following activation of the NLRP3 inflamma-
some and consequent cell death by pyroproptosis (12). Serum 
(200 mL) was incubated for 1 h with 5 mL of PE anti-ASC (TMS-1) 
antibody (Cat. 653904, BioLegend, UK). Flow cytometry was 
performed on a LSRII (BD Biosciences, UK). Non-fluorescent 
microspheres (1 mm) (Cat. F13838 Thermo Fisher Scientific, 
UK) were used for gating and ASC specks were quantified in 
comparison to healthy controls (ASC speck/mL) as previously 
described (11). We found that patient serum contained signifi-
cantly higher numbers of ASC specks compared with our healthy 
control range (Figure 3I).
With the recent discovery of A20 haploinsuffiency underlin-
ing an early-onset autoinflammatory disease (4), relatively few 
variants are currently identified as disease causing. We wondered 
what genetic variants are likely to be seen clinically as disease 
causing in future cases. Population genetics data from GnomAD 
were used to define the mutation rate residue frequencies of 
A20 (7). A map of both genetic conservation and most probable 
disease-causing variants is illustrated in Figure 4 in context with 
the known functional domains of A20. Raw data and reference 
values are provided in Table S1 in Supplementary Material. 
GnomAD was queried to identify conserved residues using a 
Boolean score C (0 or 1, although allele frequency can be substi-
tuted). Regions with no reported variants are highlighted in red 
(score 1) on the conserved residues heatmap. The gene-specific 
mutation rate of each residue was calculated from allele frequen-
cies. The gene-specific residue frequency was found. Shown 
in Table S1 in Supplementary Material, these values together 
calculate the most probable disease-causing variants which have 
not yet been identified in patients (13). The mutation rate residue 
frequency (MRF) heatmap displays the raw calculated likelihood 
of variation. For visualization, a noise reduction method was also 
applied where the average MRF per 0.5% interval is displayed 
with a cutoff threshold at the 75th percentile as shown in Table S1 
in Supplementary Material. The resulting MRF heatmap allows 
visualization of the most probable mutations which correctly 
identified variants in the ovarian tumor domain as most likely 
to present clinically as confirmed in a recent extended report by 
Aeschlimann et al. (14).
4. DISCUSSION
Unlike other monogenic autoinflammatory disorders, HA20 seems 
to be associated with broad clinical phenotypes, ranging from 
typical autoinflammatory conditions such as JIA to more tradi-
tional autoimmune diseases such as SLE. There is one reported 
case where prior clinical diagnosis could not be established, but 
the label of undifferentiated complex autoimmune disease was 
used to describe multitude of clinical signs and complications 
(15). There is also a single case of 7-month-old Japanese child who 
presented with typical clinical and laboratory features suggestive 
of autoimmune lymphoproliferative syndrome, but subsequent 
genetic testing showed heterozygous mutation in TNFAIP3 
resulting in HA20 diagnosis (16). Another Japanese group has 
just recently published a report on additional 22 cases with con-
firmed HA20. Most of the patients reported in the study had BD 
phenotype, like the original cohort reported by Zhou et al. (4), but 
they also described individuals presenting with SLE, auto immune 
hepatitis, nephritic syndrome, and Hashimoto’s thyroiditis (6). 
Perhaps this is not entirely surprising since common variants in 
TNFAIP3 have also been associated with several autoimmune 
diseases including SLE, RA, and psoriasis (5). Furthermore, 
murine studies have demonstrated that the disease phenotype 
might depend on the predominant cell type that is affected. 
Homozygous A20 deficiency in mice results in early-onset 
systemic autoinflammatory disease (17). Cell-specific ablation 
of murine A20 causes disease features representative of clinical 
presentation in human (2, 5). Mice that have A20 deficiency in 
myeloid cells develop polyarthritis, similar to RA in humans and 
murine intestinal inflammation is seen in enterocyte-specific 
A20 deficiency (18, 19). Cell-specific A20 deficiency in B cell or 
dendritic cell also produces tissue-dependent response with the 
development of autoantibodies (20, 21). It is therefore probable 
that additional factors, likely both genetic and environmental, 
play an important role in determining the final disease phenotype 
FIGURE 3 | Pro-inflammatory response in A20-deficient patient. Cytokines were measured by ELISA using supernatant from patient and healthy donors. The 
median confidence interval presented from two separate patient samples. PBMCs were treated with or without MCC950 (NLRP3 inhibitor) and stimulated for 4 h 
with LPS (10 ng/mL) followed by 1 h ATP (1 mM). Pro-inflammatory responses to NLRP3-dependent activation of (A) IL-1β and (B) IL-18, and in measurements of 
(C) IL-6, (D) TNFα, (E) IL-10, (F) IL-8 xtbf, (G) IL-17α, and (H) IL-1α. The median confidence interval or repeated patient measurements is presented. A two-way 
ANOVA statistical test was performed (*p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001). (I) ASC specks found in the HA20 patient at twice the normal range 
indicate NLRP3 inflammasome activation and pyroptosis. Treatment concentrations as described in panel (A). Measurements were taken for 7 CAPS patients which 
also represent a pro-inflammatory response although not as profound as the HA20 response. ASC specs were measured as previously described (11).
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in HA20. The heterogeneity of HA20 can be also seen within the 
same family, as illustrated here, with clinical presentation varying 
from periodic fever-like illness, AOSD to RA.
There is no standardized treatment for HA20 patients. In 
general, therapeutic approaches have been guided by the patients’ 
pre dominant clinical phenotypes. Most patients respond to 
corti co steroids; however, there is significant toxicity associated 
with this therapy since it is often required on a long-term basis. 
Interestingly, there seems to be a heterogeneous response to 
colchicine, which is traditionally mainly effective in FMF, and has 
little or no role in treatment of other hereditary fever syndromes. 
The efficacy in HA20 is at best partial, but some cases, like the 
younger sibling we presented here might have a more profound 
response. More recently, functional cytokine assays which have 
demonstrated elevated pro-inflammatory cytokine responses 
(4, 5), therefore supporting a more targeted treatment approach. 
We have also found increased pro-inflammatory responses in 
IL-1β, IL-18, TNFα, IL-10, IL-17α, IL-1α, and IL-8, but interest-
ingly not in IL-6. However, at the time of testing, the patient was 
on tocilizumab, which could have interfered with the functional 
study. Nevertheless, IL-1β, which is typically upstream of IL-6 
and stimulates the secretion of this cytokine, was increased in 
our patient and therefore there is biological plausibility for using 
anti-IL6 blockade. Other biological therapies such as anti-TNF 
and anti-IL-1 have also been effective in suppressing the systemic 
inflammation in number of patients with HA20 (14). Patients 
with severe and treatment-refractory disease might be considered 
for hematopoietic stem cell transplant.
Considering that HA20 has such a heterogeneous clinical 
presentation, pre-selection of patients for genetic testing, 
based purely on clinical features, is not likely to be sensitive 
enough to pick up all relevant cases. Conversely, genetic 
FIGURE 4 | A20 conservation and mutation rate residue frequency. (Top) Gene structure with functional domains. (Heatmap 1) Population genetics conservation 
rate, non-conserved 0 and conserved 1. (Heatmap 2) Raw MRF score prediction for conserved residues, graded 0 to 0.05. (Heatmap 3) MRF score averaged with 
0.5% intervals for each respective gene and cutoff below 75th percentile, graded 0 to 0.045 (noise reduction method). Population genetics data used GnomAD 
(version r2.0.2); median number of alleles was 245,478 (SD 97,833) covering the TNFAIP3 canonical transcript ENST00000237289 (GRCh37 6:138188351—
138204449). Filtering retained variants with the identifiers: frameshift, inframe deletion, inframe insertion, missense, stop lost, or stop gained. Reference FASTA was 
sourced from Ensembl TNFAIP3-201 ENST00000237289.8 [HGNC:11896].
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testing is increasingly performed using gene panels or even 
whole exome/genome sequencing. Consequently, potentially 
pathogenic heterzygous variants in TNFAIP3 might be found 
in patients who seemingly do not appear to have obvious HA20 
phenotype. To complicate matters further, somatic pathogenic 
mutations in TNFAIP3 have been identified in lymphomas 
7Lawless et al. AOSD due to HA20
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(22). As we have seen from the murine studies, the phenotypic 
effects of such mutations might be cell-type dependent. For 
example, myeloid-restricted mutations in the NLRP3 gene have 
now been widely accepted to cause an acquired form of CAPS 
(23). It is certainly possible to envisage similar situation aris-
ing with somatic mutations in TNFAIP3 restricted to relevant 
cell types. This challenge requires deep sequencing on a pro-
inflammatory gene panel with bioinformatic analysis tailored 
to somatic variant calling.
Most patients to date have been reported with heterozygous 
loss-of-function truncating variants. Genetic diagnosis will be 
difficult in the case of de novo mutation. Hypomorphic muta-
tions are an important consideration for A20 deficiency. Highly 
conserved residues indicate gene regions of essentiality. However, 
population genetics data from GnomAD show 47.3% conserva-
tion across A20; a challenge for pre-emptive functional study. 
To tackle the void of interpreting novel variants of unknown 
significance, we applied mutation rate residue frequencies to 
conserved coding regions and identify the most likely variants 
to present clinically.
5. CONCLUSION
We identify a case of HA20, which responded positively to anti-
IL6 receptor treatment. This report expands on the heterogene-
ity of HA20 phenotypes. We expect to see reports of disease 
due to missense mutation and provide a map of most probable 
variants.
ETHICS STATEMENT
The study was performed in accordance with the Declaration of 
Helsinki. Human samples were collected with ethical approval 
from Leeds Ethics Committees, with written informed consent 
from participants before inclusion in the study. A written informed 
consent was obtained from the participant for the publication of 
this case report.
AUTHOR CONTRIBUTIONS
SS designed the study, collected clinical data, and was the principal 
clinician in charge of the patients’ care. DL, RA, and SS wrote the 
manuscript. DL performed genetic analysis and protein quantifi-
cation. SP and TS performed whole blood inflammasome-related 
and cytokine experiments. SP performed ASC speck experiments 
and flow cytometry experiments. LO performed flow cytometry 
experiments.
ACKNOWLEDGMENTS
The authors would like to thank the patient and their family as 
well as all physicians caring for them.
FUNDING
This work was supported by grants from The University of Leeds, 
Leeds Charitable Foundation, National Institute of Health Research 
(NIHR). The views expressed are those of the author(s) and not 
necessarily those of the NHS, the NIHR or the Depart ment of 
Health.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01527/
full#supplementary-material.
TABLE S1 | MRF calculation and reference values. A complete list of calculated 
mutation rate residue frequencies (MRF) from A20 used for illustration of 
Figure 4. Population genetics data were acquired from GnomAD (version r2.0.2). 
Mutation rates and residue frequencies specific to TNFAIP3 were calculated.  
A Boolean scoring method was applied for conserved gene regions, scored as 0 
and multiple variants per residue scored as 1 (for clarity, the variance frequency 
is also provided for low allele frequency rare variants). The MRF score predicts 
the likelihood of mutation for conserved residues. Known functional residues 
were sourced from UniProt and used for domain color coding in Figure 4. High 
scoring MRF indicate most probable variants for amino acids which are reported 
as non-mutated on GnomAD.
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